CDKN2A and prostate carcinoma: By combining GSTP1 hypermethylation with (1) the DNA methylation levels of the TSGs APC and EDNRB [71], (2) the DNA methylation levels of CDKN2A, ARF and MGMT [72], or (3) the levels of the prostate-specific antigen, prostate cancer diagnosis sensitivity is improved [73].